MX2016000384A - Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. - Google Patents

Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.

Info

Publication number
MX2016000384A
MX2016000384A MX2016000384A MX2016000384A MX2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A
Authority
MX
Mexico
Prior art keywords
vegf antagonist
treating
chorioretinal neovascular
child
permeability disorders
Prior art date
Application number
MX2016000384A
Other languages
English (en)
Inventor
Sergey Aksenov
Gabriela Burian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016000384A publication Critical patent/MX2016000384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se refiere al uso de un antagonista de VEGF en el tratamiento de trastornos neovasculares o permeabilidad coriorretiniana en los niños. En particular, la presente invención proporciona un antagonista de VEGF para su uso en un método para tratar a un niño que tiene CNV o ME, en el que dicho método comprende la administración al ojo de un niño un antagonista de VEGF que, o bien no alcanza, o se elimina rápidamente de la circulación sistémica. El antagonista de VEGF puede ser administrado por vía intravítrea, por ejemplo, a través de inyección, o por vía tópica, por ejemplo, en forma de gotas para los ojos. La presente invención proporciona además el uso de un antagonista de VEGF en la fabricación de un medicamento para tratar a un niño que tiene un trastorno neovascular o permeabilidad coriorretiniana.
MX2016000384A 2013-07-11 2014-07-09 Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. MX2016000384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845064P 2013-07-11 2013-07-11
PCT/IB2014/062978 WO2015004616A1 (en) 2013-07-11 2014-07-09 Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients

Publications (1)

Publication Number Publication Date
MX2016000384A true MX2016000384A (es) 2016-04-29

Family

ID=51211282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000384A MX2016000384A (es) 2013-07-11 2014-07-09 Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.

Country Status (11)

Country Link
US (2) US20160168240A1 (es)
EP (1) EP3019526A1 (es)
JP (1) JP2016528202A (es)
KR (1) KR20160029794A (es)
CN (1) CN105377891A (es)
AU (2) AU2014288837A1 (es)
BR (1) BR112016000177A2 (es)
CA (1) CA2917807A1 (es)
MX (1) MX2016000384A (es)
RU (1) RU2676274C2 (es)
WO (1) WO2015004616A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2371865T3 (pl) 2006-04-07 2018-02-28 Aerpio Therapeutics, Inc. Przeciwciała wiążące ludzką białkową fosfatazę tyrozynową beta (HPTP-β) oraz ich zastosowania
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
SG172313A1 (en) 2009-07-06 2011-07-28 Akebia Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
EP3143044A1 (en) * 2014-05-12 2017-03-22 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2998673C (en) 2015-09-23 2023-12-12 Aerpio Therapeutics, Inc. Methods of treating intraocular pressure with activators of tie-2
CN108290004A (zh) * 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
CN108697792A (zh) * 2015-11-19 2018-10-23 珠海泰瑞尚生物医药科技有限公司 用于结合vegf的方法和组合物
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
US10654922B2 (en) * 2016-05-13 2020-05-19 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3573641A4 (en) * 2017-01-25 2020-11-11 Iconic Therapeutics, Inc. TREATMENT METHODS FOR DISORDERS ASSOCIATED WITH ANGIOGENESIS AND NEOVASCULARIZATION
JP2022530657A (ja) 2019-04-29 2022-06-30 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
RU2762991C1 (ru) * 2021-09-06 2021-12-24 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения макулярного отека вследствие окклюзии ветви центральной вены сетчатки в сочетании с ретинальной артериолярной макроаневризмой

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404297B1 (en) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
PL1767546T3 (pl) 2004-06-08 2012-07-31 Chengdu Kanghong Biotechnologies Co Ltd Hamujące angiogenezę białka chimeryczne i ich zastosowanie
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US20110054031A1 (en) * 2008-02-21 2011-03-03 Ista Pharmaceuticals, Inc. Ophthalmic NSAIDS as Adjuvants
US8535681B2 (en) * 2008-10-16 2013-09-17 Kathleen Cogan Farinas Sustained drug delivery system
KR101698362B1 (ko) * 2008-11-03 2017-01-20 몰리큘라 파트너스 아게 Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
KR101692459B1 (ko) * 2008-12-16 2017-01-03 밸리언트 파마슈티컬즈 인터내셔널, 인코퍼레이션 원치않는 맥락막 혈관신생의 치료시 광역학 요법과 항ｖｅｇｆ제의 복합 요법
WO2010088548A1 (en) 2009-01-29 2010-08-05 Forsight Labs, Llc Posterior segment drug delivery
CA2760687A1 (en) * 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"

Also Published As

Publication number Publication date
BR112016000177A2 (pt) 2017-12-12
EP3019526A1 (en) 2016-05-18
WO2015004616A1 (en) 2015-01-15
AU2017203923B2 (en) 2018-10-18
KR20160029794A (ko) 2016-03-15
RU2676274C2 (ru) 2018-12-27
CN105377891A (zh) 2016-03-02
CA2917807A1 (en) 2015-01-15
US20160168240A1 (en) 2016-06-16
AU2017203923A1 (en) 2017-07-06
US20180194835A1 (en) 2018-07-12
RU2016104397A3 (es) 2018-05-31
AU2014288837A1 (en) 2015-12-10
RU2016104397A (ru) 2017-08-16
JP2016528202A (ja) 2016-09-15

Similar Documents

Publication Publication Date Title
MX2016000384A (es) Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.
MX2016000385A (es) Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad.
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
JP2012046524A5 (es)
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
PH12015502773A1 (en) Methods for treating or preventing opthalmological conditions
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
HK1256027A1 (zh) 用於以輸注或注射形式進行靜脈給藥的左西孟旦以及輸注濃縮液的改善配方
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
MX2020004106A (es) Metodo de tratamiento de trastornos neurodegenerativos.
GB201518170D0 (en) Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
WO2012158776A3 (en) Combination therapy for treatment of cancer
AR102494A1 (es) Métodos para tratar enfermedades oculares
WO2014149998A8 (en) Systemic administration of androgen in treating dry eye syndrome